Tag Archives: Watchman

El cierre de orejuela es seguro con los nuevos dispositivos

Intracardiac Echocardiography to Guide Watchman Left Atrial Appendix Closure: Safe and Effective?

Intracardiac Echocardiography to Guide Watchman Left Atrial Appendix Closure: Safe and Effective?

Left atrial appendix closure (LAAC) has become a frequent intervention for stroke prevention in patients with atrial fibrillation (AF) that make poor candidates for anticoagulation. However, it presents a complication with negative impact on procedural outcomes which is peridevice leak.  To reduce these complications, we use intra-procedural imaging, the transesophageal echocardiogram (TEE) being the most

cierre_orejuela_stroke

Antithrombotic Therapy Post Percutaneous Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAO) with Watchman has FDA approval since March 2015, having shown, in the PROTECT-AF and PREVAIL studies, reduced risk of atrial fibrillation driven stroke, by excluding the left atrial appendage form systemic circulation.  Both studies used post procedure standardized protocols involving followup at 45 days and 6 months, imaging, and

cierre_orejuela_stroke

PRAGUE-17: Appendage Closure vs. Direct Anticoagulant Agents

After four years of follow-up, the PRAGUE-17 study showed that appendage closure is non-inferior to direct anticoagulant agents (non-warfarin oral anticoagulants, NOAC) to prevent major neurological events, cardiovascular events, and bleeding events in patients at high risk of atrial fibrillation. Appendage studies were compared with warfarin studies—it was necessary to update anticoagulant agents and reach

AMULET vs WATCHMAN. Los dispositivos de cierre de orejuela cabeza a cabeza

AMULET vs. WATCHMAN: Appendage Closure Devices, Head to Head

This research was designed to compare the double closure system of the AMULET device with the WATCHMAN (an evidence-backed proven device). In that context, to prevent stroke in patients with non-valvular atrial fibrillation, the Amplatzer AMULET device was non-inferior in both safety and efficacy compared with the WATCHMAN. Atrial appendage occlusion in itself improved with

Resultados a 5 años del cierre de orejuela

Five-Year Outcomes for Appendage Closure

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial appendage closure with the Watchman device was equivalent to warfarin for preventing stroke in atrial fibrillation, but it had a high rate of peri-procedural complications. The follow-up randomized trial was PREVAIL (Evaluation of the

TCT 2017 | Resultados finales del dispositivo Watchman

TCT 2017 | PREVAIL: Final Outcomes of the Watchman Device

Courtesy of SBHCI. The final 5-year outcomes of the PROTECT AF and PREVAIL studies (which assessed the left atrial appendage closure device Watchman) continues to show similar stroke prevention rate to that of warfarin, though with a clear reduction in bleeding. The meta-analysis showed a significant reduction in hemorrhagic stroke (0.17% vs 0.87%), non-procedure related

Top